Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Biotech Financing in the Credit Crisis - Strategies for a radically altered landscape (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 22/12/2008
- Report Title: Biotech Financing in the Credit Crisis - Strategies for a radically altered landscape
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 93
Offer! 15% discount on this report. The price will update once it is in your shopping cart.
Introduction
Since the financial meltdown, the relationship between Pharma and Biotech has been turned on its head. Previously, pharma companies had no choice but to license Biotech drugs at high prices in order to fill their sparse late stage pipelines.
Scope
*Overview licensing trends up until the credit crisis
*Strategic analysis of biotech's funding crisis
*Insight into how the biopharma market is expected to change and adapt
*Recommendations and potential financial solutions for biotech
Highlights
While Pharma is likely to prefer acquiring biotech targets out right, rather than navigating the road of complex licensing agreements, Datamonitor expects that licensing agreements will remain among Pharma and self sufficient biotech companies. Although snapping up struggling Biotechs through M&A will be a priority for Pharma.
Biotech companies are tackling their funding crises on two fronts; firstly, by cutting costs and reducing their high cash-burn rates, and secondly attempting to access quick cash from external sources. However, this is becoming a tough task.
The lack of deals on the horizon, Biotech's funding crisis, and subsequent loss of confidence in the industry, have all led the market cap of non-profitable US biotech companies to fall by a third since September 2008.
Reasons to Purchase
*Understand how licensing trends have evolved in recent years, and what impact the financial crisis has had
*Assess how Pharma and Biotech's relationship has changed and the repercussions of this
*Identify cost saving and cash raising strategies in order to weather the funding crisis
Since the financial meltdown, the relationship between Pharma and Biotech has been turned on its head. Previously, pharma companies had no choice but to license Biotech drugs at high prices in order to fill their sparse late stage pipelines.
Scope
*Overview licensing trends up until the credit crisis
*Strategic analysis of biotech's funding crisis
*Insight into how the biopharma market is expected to change and adapt
*Recommendations and potential financial solutions for biotech
Highlights
While Pharma is likely to prefer acquiring biotech targets out right, rather than navigating the road of complex licensing agreements, Datamonitor expects that licensing agreements will remain among Pharma and self sufficient biotech companies. Although snapping up struggling Biotechs through M&A will be a priority for Pharma.
Biotech companies are tackling their funding crises on two fronts; firstly, by cutting costs and reducing their high cash-burn rates, and secondly attempting to access quick cash from external sources. However, this is becoming a tough task.
The lack of deals on the horizon, Biotech's funding crisis, and subsequent loss of confidence in the industry, have all led the market cap of non-profitable US biotech companies to fall by a third since September 2008.
Reasons to Purchase
*Understand how licensing trends have evolved in recent years, and what impact the financial crisis has had
*Assess how Pharma and Biotech's relationship has changed and the repercussions of this
*Identify cost saving and cash raising strategies in order to weather the funding crisis
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
